Benzinga | Aug 4, 2020 07:18AM EDT

Karyopharm Therapeutics Q2 EPS $(0.63) Misses $(0.58) Estimate, Sales $33.51M Beat $27.42M Estimate

Karyopharm Therapeutics (NASDAQ:KPTI) reported quarterly losses of $(0.63) per share which missed the analyst consensus estimate of $(0.58) by 8.62 percent. This is a 11.27 percent increase over losses of $(0.71) per share from the same period last year. The company reported quarterly sales of $33.51 million which beat the analyst consensus estimate of $27.42 million by 22.22 percent. This is a 253.04 percent increase over sales of $9.49 million the same period last year.